Highlights WuXi Biologics (Cayman) Inc. OTC Markets

Stocks

WXXW.Y

US98260N1081

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:59:59 2026-06-10 pm EDT			5-day change	1st Jan Change
7.620 ^USD	+0.26%		-7.19%	-4.75%

Jun. 05	Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub	CI
May. 31	Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth	RE

Highlights

Jun. 05	Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub	CI
May. 31	Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth	RE
May. 27	Wuxi Biologics Achieves Gmp Release of 18Th Drug Product Facility and Advances Integrated Drug Substance to Drug Product Capabilities	CI
May. 25	WuXi Biologics to Conduct Up to $400 Million Share Buyback; Shares Up 4%	MT
May. 25	Wuxi Biologics to repurchase shares up to US$400 million in open market	RE
May. 25	WuXi Biologics Plans to Buy Back Up to US$400 Million of Shares	DJ
Apr. 24	WuXi Biologics Achieves Structural Completion and Key Equipment Arrival At Chengdu Microbial Commercial Manufacturing Site	CI
Mar. 24	WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 24	WuXi Biologics' Profit Climbs 46% in 2025	MT
Mar. 24	Wuxi Biologics posts FY revenue of RMB21,790.0 million	RE
Mar. 13	WuXi Biologics Signs Antibody Development Deal with Earendil Labs	MT
Mar. 12	Earendil Labs and Wuxi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Bispecific Multispecific Antibodies and Adcs	CI
Feb. 10	WuXi Biologics Forecasts Higher Profit, Revenue in 2025	MT
Feb. 10	Wuxi Biologics FY revenue RMB21,790 million	RE
Feb. 10	WuXi Biologics Inc. Provides Unaudited Consolidated Earnings Guidance for the Year Ended December 31, 2025	CI
Feb. 02	WuXi Biologics Inc. and Vertex Pharmaceuticals Incorporated Sign License and Research Service Agreement for T-Cell Engager	CI
Jan. 28	WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody	CI
Jan. 12	Wuxi Biologics Launches Digital Twin Platform Patrolab Designed to Transform Bioprocessing and Manufacturing	CI
Dec. 02	Wuxi Biologics Extends Global CRDMO Network to Qatar Through Strategic MOU Signed with Qatar Free Zones Authority	CI
25-09-25	WuXi Biologics Launches WuXia 4.0, Targeted Integration Cell Line Platform TrueSite TI, to Accelerate Biologics Development with High Titer and Superior Stability	CI
25-09-09	WuXi Biologics Launches Green CRDMO White Paper to Advance Sustainability in Biologics Industry	CI
25-08-19	Wuxi Biologics posts H1 net income RMB 2,756.6 million	RE
25-08-19	WuXi Biologics Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-08-19	WuXi Biologics's Profit Surges 56% in H1	MT
25-08-19	Tranche Update on WuXi Biologics Inc.'s Equity Buyback Plan announced on September 2, 2024.	CI